Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
Where next for TIGIT?
The implosion of Skyscraper-06 has a direct impact on at least two other TIGIT players.
Roche reins in the TIGIT expectations
Skyscraper-06 blows up spectacularly, and that’s bad news for Skyscraper-01.
Regeneron gets a European reprieve
The EU recommendation for odronextamab comes after a US rejection in March.
Bristol overtakes Amgen in colorectal
Meanwhile, Bristol’s other competition in this disease looks set to come from China.
Tempest’s pivotal amezalpat conundrum
How does the micro-cap biotech now finance a 700-patient phase 3 study?
EHA 2024 – J&J bows out as Roche looks to confirm
Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.
